Inmed Pharmaceuticals Stock Market Value
| INM Stock | USD 0.85 0.03 3.41% |
| Symbol | InMed |
Will Biotechnology sector continue expanding? Could InMed diversify its offerings? Factors like these will boost the valuation of InMed Pharmaceuticals. Market participants price InMed higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every InMed Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (6.09) | Revenue Per Share | Quarterly Revenue Growth (0.26) | Return On Assets | Return On Equity |
Understanding InMed Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects InMed's accounting equity. The concept of intrinsic value - what InMed Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push InMed Pharmaceuticals' price substantially above or below its fundamental value.
Please note, there is a significant difference between InMed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if InMed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, InMed Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
InMed Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to InMed Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of InMed Pharmaceuticals.
| 12/02/2025 |
| 03/02/2026 |
If you would invest 0.00 in InMed Pharmaceuticals on December 2, 2025 and sell it all today you would earn a total of 0.00 from holding InMed Pharmaceuticals or generate 0.0% return on investment in InMed Pharmaceuticals over 90 days. InMed Pharmaceuticals is related to or competes with Aprea Therapeutics, Adial Pharmaceuticals, Kiora Pharmaceuticals, Cardio Diagnostics, and Phio Pharmaceuticals. InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products More
InMed Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure InMed Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess InMed Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.09) | |||
| Maximum Drawdown | 30.84 | |||
| Value At Risk | (9.09) | |||
| Potential Upside | 7.48 |
InMed Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for InMed Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as InMed Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use InMed Pharmaceuticals historical prices to predict the future InMed Pharmaceuticals' volatility.| Risk Adjusted Performance | (0.05) | |||
| Jensen Alpha | (0.52) | |||
| Total Risk Alpha | (0.94) | |||
| Treynor Ratio | (0.25) |
InMed Pharmaceuticals March 2, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | (0.24) | |||
| Mean Deviation | 3.83 | |||
| Coefficient Of Variation | (1,332) | |||
| Standard Deviation | 5.17 | |||
| Variance | 26.71 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.52) | |||
| Total Risk Alpha | (0.94) | |||
| Treynor Ratio | (0.25) | |||
| Maximum Drawdown | 30.84 | |||
| Value At Risk | (9.09) | |||
| Potential Upside | 7.48 | |||
| Skewness | (0.1) | |||
| Kurtosis | 1.11 |
InMed Pharmaceuticals Backtested Returns
InMed Pharmaceuticals holds Efficiency (Sharpe) Ratio of -0.12, which attests that the entity had a -0.12 % return per unit of volatility over the last 3 months. InMed Pharmaceuticals exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out InMed Pharmaceuticals' market risk adjusted performance of (0.24), and Risk Adjusted Performance of (0.05) to validate the risk estimate we provide. The company retains a Market Volatility (i.e., Beta) of 1.59, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, InMed Pharmaceuticals will likely underperform. At this point, InMed Pharmaceuticals has a negative expected return of -0.6%. Please make sure to check out InMed Pharmaceuticals' potential upside, as well as the relationship between the rate of daily change and period momentum indicator , to decide if InMed Pharmaceuticals performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.77 |
Good predictability
InMed Pharmaceuticals has good predictability. Overlapping area represents the amount of predictability between InMed Pharmaceuticals time series from 2nd of December 2025 to 16th of January 2026 and 16th of January 2026 to 2nd of March 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of InMed Pharmaceuticals price movement. The serial correlation of 0.77 indicates that around 77.0% of current InMed Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.77 | |
| Spearman Rank Test | 0.59 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out InMed Pharmaceuticals Correlation, InMed Pharmaceuticals Volatility and InMed Pharmaceuticals Performance module to complement your research on InMed Pharmaceuticals. To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
InMed Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.